Jan 17 (Reuters) - Sunesis Pharmaceuticals Inc ::SUNESIS ANNOUNCES PRICING OF $20 MILLION OFFERING OF SECURITIES.ANNOUNCED PRICING OF UNDERWRITTEN PUBLIC OFFERINGS OF 23 MILLION SHARES OF ITS COMMON STOCK AT $0.50.PRICING OF UNDERWRITTEN PUBLIC OFFERINGS OF 17,000 SHARES OF ITS NON-VOTING SERIES E CONVERTIBLE PREFERRED STOCK AT $500.SUNESIS EXPECTS TO RECEIVE COMBINED GROSS PROCEEDS OF APPROXIMATELY $20 MILLION FROM THESE OFFERINGS.
Full Article
Jan 17 (Reuters) - Sunesis Pharmaceuticals Inc ::SUNESIS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK AND PREFERRED STOCK.
Full Article
Dec 4 (Reuters) - Sunesis Pharmaceuticals Inc ::SUNESIS PHARMACEUTICALS INC - DANIEL SWISHER RESIGNS AS CEO EFFECTIVE END OF 2017.SUNESIS PHARMACEUTICALS INC - SWISHER TO REMAIN WITH SUNESIS AS A STRATEGIC ADVISOR.SUNESIS PHARMACEUTICALS INC - BOARD MEMBER DAYTON MISFELDT APPOINTED INTERIM CEO EFFECTIVE JANUARY 2018.
Full Article
Nov 30 (Reuters) - Sunesis Pharmaceuticals Inc ::SUNESIS PHARMACEUTICALS APPOINTS WILLIAM QUINN AS CHIEF FINANCIAL OFFICER AND SENIOR VICE PRESIDENT, FINANCE AND CORPORATE DEVELOPMENT.SUNESIS PHARMACEUTICALS INC - WILLIAM QUINN MOST RECENTLY SERVING AS CEO AND CO-FOUNDER OF PRIVATE CANCER IMMUNOTHERAPY COMPANY BULLET BIOTECHNOLOGY.
Full Article
Nov 2 (Reuters) - Sunesis Pharmaceuticals Inc :Sunesis Pharmaceuticals reports third quarter 2017 financial results and recent highlights.Sunesis Pharmaceuticals Inc qtrly loss per share $0.43.Sunesis Pharmaceuticals Inc- pro-forma Sept 30, 2017 cash, cash equivalents and marketable securities of $37.1 million is expected to fund co into 2019.
Full Article
Oct 25 (Reuters) - Sunesis Pharmaceuticals Inc ::Sunesis announces pricing of $20 million offering of securities.Sunesis Pharmaceuticals Inc - pricing of underwritten public offerings of 7.5 million shares and accompanying warrants to purchase 3.8 million shares.Sunesis Pharmaceuticals- also priced 2,500 shares of non-voting series D convertible preferred stock, accompanying warrants to purchase 1.3 million shares.
Full Article
Oct 25 (Reuters) - Sunesis Pharmaceuticals Inc :Sunesis announces proposed public offering of common stock, preferred stock and warrants.Sunesis Pharmaceuticals Inc - anticipates using net proceeds from proposed offerings to fund development of sns-062, additional kinase inhibitor programs.
Full Article
Earnings vs. 
Estimates